# US 2013/0157934 A1 · Glucagon Superfamily Peptides Exhibiting Glucocorticoid Receptor Activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157934 A1
- Document ID: US20130157934A1
- Status: Published application
- Kind: A1
- Application number: 13/679,121
- Filed: 2012-11-16
- Published: 2013-06-20
- Earliest claimed: 2011-11-17
- Assignees: Indiana University Research and Technology Corporation
- Inventors: Richard D. DiMARCHI; Bin YANG
- Web page: https://patentgrep.com/patent/US20130157934A1

## CPC

- C07K 14/605: Glucagons
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/715: containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.

## Claims

### Claim 1

A compound comprising the structure Q-L-Y;
wherein Q is a glucagon superfamily peptide;
Y is a GR ligand which activates a glucocorticoid receptor with an EC50 of about 1 μM or less, and has a molecular weight of up to about 1000 daltons; and
L is a linking group or a bond, wherein Q-L is attached to position 3 or 17 of the GR ligand.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Q exhibits at least 0.1% of the activity of native GLP-1 at the GLP-1 receptor, at least 0.1% of the activity of native glucagon at the glucagon receptor, or at least 0.1% of the activity of native GIP at the GIP receptor, or a combination thereof.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein Q has an EC50 at the GLP-1 receptor within 10-fold of the EC50 of Y at the glucocorticoid receptor, an EC50 at the glucagon receptor within 10-fold of the EC50 of Y at the glucocorticoid receptor, or an EC50 at the GIP receptor within 10-fold of the EC50 of Y at the glucocorticoid receptor, or a combination thereof.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The compound of claim 1, wherein Y is a compound of Formula C.

### Claim 9 (depends on 8)

The compound of claim 8, wherein Y is cortisol or a derivative thereof.

### Claim 10 (depends on 9)

The compound of claim 9, wherein the cortisol or derivative thereof is selected from the group consisting of cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, and dexamethasone.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The compound of claim 1, wherein L is stable in vivo, hydrolyzable in vivo, or metastable in vivo.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 13)

The compound of claim 13, wherein L comprises an ether moiety, an amide moiety, an ester moiety, an acid-labile moiety, a reduction-labile moiety, an enzyme-labile moiety, a hydrazone moiety, a disulfide moiety, or a cathepsin-cleavable moiety.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 10)

The compound of claim 10, wherein the compound comprises the structure (I):
wherein
B′ is an amino- or thiol-containing side chain of an amino acid of Q, wherein
B′ is the side chain of an amino acid corresponding to position 10, 20, 24, 30, 37, 38, 39, 40, 41, 42, or 43 of a sequence comprising native glucagon;
L is a bond,
and,
x is C1-C10 alkylene (e.g., C1-C6 alkylene), C1-C10 alkenylene, or C1-C10 alkynylene; or
(II):
wherein
B″ is a thiol-containing side chain of an amino acid of Q, wherein B″ is the side chain of an amino acid corresponding to position 10, 20, 24, 30, 37, 38, 39, 40, 41, 42, or 43 of a sequence comprising native glucagon, and
y is C1-C10 alkylene (e.g., C1-6), C1-C10 alkenylene, or C1-C10 alkynylene.

### Claim 21 (depends on 20)

The compound of claim 20, wherein
x is C1-C6 alkylene;
B′ is
and,
z is C1-C6 alkylene.

### Claim 22 (depends on 21)

The compound of claim 21, wherein the compound comprises the structure:

### Claim 23 (depends on 22)

The compound of claim 22, wherein the compound comprises the structure:

### Claim 24

(canceled)

### Claim 25 (depends on 20)

The compound of claim 20, wherein the compound comprises the structure:

### Claim 26 (depends on 10)

The compound of claim 10, wherein Q comprises
(I) an amino acid sequence at least 50% identical to native glucagon that retains the alpha-helix conformation of the amino acids corresponding to amino acids 12-29 of native glucagon (SEQ ID NO: 1601);
(II) an amino acid sequence at least 50% identical to native GLP-1 that retains the alpha-helix conformation of the amino acids corresponding to amino acids 12-29 of native GLP-1 (SEQ ID NO: 1603); or
(III) the amino acid sequence:
X1-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Z (SEQ ID NO: 839) with 1 to 3 amino acid modifications thereto,
(a) wherein X1 and/or X2 is a non-native amino acid (relative to SEQ ID NO: 1601) that reduces susceptibility of the glucagon peptide to cleavage by dipeptidyl peptidase IV (DPP-IV),
(b) wherein Z is selected from the group consisting of —COOH, -Asn-COOH, Asn-Thr-COOH, and W—COOH, wherein W is 1 to 2 amino acids or GPSSGAPPPS,
(c) wherein Q comprises a modification selected from the group consisting of:
(i) a lactam bridge between the side chains of amino acids at positions i and i+4, wherein i is 12, 16, 20 or 24, and
(ii) one, two, three, or all of the amino acids at positions 16, 20, 21, and 24 of the glucagon peptide is substituted with an α,α-disubstituted amino acid; wherein Q exhibits glucagon agonist activity.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 26)

The compound of claim 26, wherein Q comprises the amino acid sequence of SEQ ID NO: 1601 and comprises:
(a) at least one amino acid modification selected from the group consisting of:
(i) substitution of Thr at position 29 with a charged amino acid;
(ii) substitution of Thr at position 29 with a charged amino acid selected from the group consisting of Lys, Arg, His, Asp, Glu, cysteic acid, and homocysteic acid;
(iii) substitution at position 29 with Asp, Glu, or Lys;
(iv) substitution at position 29 with Glu;
(v) insertion after position 29 of 1 to 3 charged amino acids;
(vi) insertion after position 29 of Glu or Lys;
(vii) insertion after position 29 of Gly-Lys, or Lys-Lys;
(viii) substitution of Gln at position 3 with an amino acid comprising a side chain of Structure I, II, or III:
wherein R1 is C0-3 alkyl or C0-3 heteroalkyl; R2 is NHR4 or C1-3 alkyl; R3 is C1-3 alkyl; R4 is H or C1-3 alkyl; X is NH, O, or S; and Y is NHR4, SR3, or OR3; and
(ix) a combination thereof;
(b) substitution of Ser at position 16 with Thr, Glu, or Aib; and at least one amino acid modification selected from the group consisting of:
(i) substitution of His at position 1 with a non-native amino acid that reduces susceptibility of the glucagon peptide to cleavage by dipeptidyl peptidase IV (DPP-IV),
(ii) substitution of Ser at position 2 with a non-native amino acid that reduces susceptibility of the glucagon peptide to cleavage by dipeptidyl peptidase IV (DPP-IV),
(iii) substitution of Thr at position 7 with Ile, Abu, or Val;
(iv) substitution of Gln at position 20 with Ser, Thr, Ala, Aib, Arg, or Lys;
(v) substitution of Met at position 27 with Leu or Nle;
(vi) deletion of amino acids at positions 28-29;
(vii) deletion of the amino acid at positions 29;
(viii) addition of the amino acid sequence GPSSGAPPPS to the C-terminus; and
(ix) addition of the amino acid sequence GPSSGAPPPSX to the C-terminus, wherein X is any amino acid; and
(x) a combination thereof;
wherein Q exhibits glucagon agonist activity.

### Claim 30 (depends on 26)

The compound of claim 26, wherein
(I) Q comprises a glucagon related peptide of SEQ ID NO: 1601, with the following modifications:
(a) an amino acid modification at position 1 that confers GIP agonist activity,
(b) a modification selected from the group consisting of:
(i) a lactam bridge between the side chains of amino acids at positions i and i+4 or between the side chains of amino acids at positions j and j+3, wherein i is 12, 13, 16, 17, 20 or 24, and wherein j is 17, and
(ii) one, two, three, or all of the amino acids at positions 16, 20, 21, and 24 of the analog is substituted with an α,α-disubstituted amino acid,
(c) 1-10 further amino acid modifications;
wherein Q exhibits activity at the GIP receptor;
(II) Q comprises the amino acid sequence:
X1-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-X3-Ser-X4-Tyr-Leu-X5-X6-X7-X8-Ala-X9-X10-Phe-X11-X12-Trp-Leu-X13-X14-X15 (SEQ ID NO: 55), or an analog thereof, wherein said analog differs from SEQ ID NO: 55 by 1 to 3 amino acid modifications, selected from positions 1, 2, 3, 5, 7, 10, 11, 13, 14, 17, 18, 19, 21, and 25, wherein:
(a) X1 is His, D-His, (Des-amino)His, hydroxyl-His, acetyl-His, homo-His, or alpha, alpha-dimethyl imidazole acetic acid (DMIA), N-methyl His, alpha-methyl His, or imidazole acetic acid;
(b) X2 is Ser, D-Ser, Ala, D-Ala, Val, Gly, N-methyl Ser, aminoisobutyric acid (Aib) or N-methyl Ala;
(c) X3, X4, X5, X10, X11, and X14 are, individually, any amino acid;
(d) X6 is Ser, Glu, Gln, homoglutamic acid or homocysteic acid;
(e) X7 is Arg, Gln, Lys, Cys, Orn, homocysteine or acetyl phenylalanine;
(f) X8 is Arg, Ala, Lys, Cys, Orn, homocysteine or acetyl phenyalanine;
(g) X9 is Gln, Lys, Arg, Orn or Citrulline;
(h) X12 is Ala, Gln, Glu, Lys, Cys, Orn, homocysteine or acetyl phenyalanine;
(i) X13 is Met, Leu or Nle;
(j) X15 is Thr, Gly, Lys, Cys, Orn, homocyesteine or acetyl phenyalanine; and
comprises one of the following modifications:
(a) deletion of amino acids at positions 28-29;
(b) deletion of the amino acid at positions 29;
(c) addition of the amino acid sequence GPSSGAPPPS to the C-terminus; and
(d) addition of the amino acid sequence GPSSGAPPPSX to the C-terminus, wherein X is any amino acid; and
(e) a combination thereof; or
(III) Q comprises an amino acid sequence that differs from SEQ ID NO: 1601 by no more than ten amino acid modifications, comprising:
(a) one or more amino acid substitutions with Aib at positions 16, 20, 21, and/or 24, and
(b) an amino acid modification at position 1 and/or 2 that provides reduced susceptibility to cleavage by dipeptidyl peptidase IV, and
comprising one or more of the following modifications:
(a) deletion of amino acids at positions 28 and 29,
(b) deletion of the amino acid at position 29,
(c) addition of the amino acid sequence GPSSGAPPPS to the C-terminus,
(d) addition of the amino acid sequence GPSSGAPPPSX to the C-terminus, wherein X is any amino acid,
(e) substitution of the C-terminal carboxyl group with an amide or carboxylic ester, and
wherein Q exhibits GLP-1 agonist activity and glucagon agonist activity.

### Claim 31 (depends on 30)

The compound of claim 30, wherein the 1-10 further amino acid modifications in (I) are selected from the group consisting of:
(i) substitution of serine at position 2 with D-Ser, Ala, D-Ala, Gly, N-methyl-Ser, Aib, Val, or ε-amino-N-butyric acid;
(ii) substitution of serine at position 16 with Glu, Gln, homoglutamic acid, homocysteic acid, Thr, Gly, or Aib;
(iii) substitution of glutamine at position 20 with Ser, Thr, Ala, Lys, Citrulline, Arg, Orn, or Aib;
(iv) substitution of methionine at position 27 with Leu;
(v) substitution of argnine at position 28 with Ala;
(vi) substitution of threonine at position 29 with Gly;
(vii) a conservative substitution at any of positions 2, 5, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 24, 27, 28, and 29;
(viii) addition of 1-21 amino acids to the C-terminus
(ix) addition of the amino acid sequence GPSSGAPPPS to the C-terminus,
(x) addition of the amino acid sequence GPSSGAPPPSX to the C-terminus, wherein X is any amino acid,
(xi) substitution of the C-terminal carboxyl group with an amide or carboxylic ester, and
(xii) a combination thereof.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 10)

The compound of claim 10, wherein L-Y is covalently conjugated to the N-terminus, C-terminus, or an amino acid side chain of Q.

### Claim 35 (depends on 10)

The compound of claim 10, wherein L-Y is conjugated to an amino acid side chain of Q that corresponds to position 10, 30, 37, 38, 39, 40, 41, 42, or 43 of native glucagon (SEQ ID NO: 1601).

### Claim 36

(canceled)

### Claim 37 (depends on 10)

A prodrug of the compound of claim 10 comprising the structure A-B, wherein
A is an amino acid or a hydroxy acid;
B is an N-alkylated amino acid linked to Q through an amide bond between a carboxyl moiety of B and an amine of Q;
A, B, or the amino acid of Q to which A-B is linked is a non-coded amino acid, further wherein the chemical cleavage half-life (t1/2) of A-B from Q is at least about 1 hour to about 1 week in PBS under physiological conditions.

### Claim 38 (depends on 37)

The compound of claim 37, wherein A-B comprises the structure:
wherein
(a) R1, R2, R4 and R8 are independently selected from the group consisting of H, C1-C18 alkyl, C2-C18 alkenyl, (C1-C18 alkyl)OH, (C1-C18 alkyl)SH, (C2-C3 alkyl)SCH3, (C1-C4 alkyl)CONH2, (C1-C4 alkyl)COOH, (C1-C4 alkyl)NH2, (C1-C4 alkyl)NHC(NH2+)NH2, (C0-C4 alkyl)(C3-C6 cycloalkyl), (C0-C4 alkyl)(C2-C5 heterocyclic), (C0-C4 alkyl)(C6-C10 aryl)R7, (C1-C4 alkyl)(C3-C9 heteroaryl), and C1-C12 alkyl(W1)C1-C12 alkyl, wherein W1 is a heteroatom selected from the group consisting of N, S and O, or
(ii) R1 and R2 together with the atoms to which they are attached form a C3-C12 cycloalkyl or aryl; or
(iii) R4 and R8 together with the atoms to which they are attached form a C3-C6 cycloalkyl;
(b) R3 is selected from the group consisting of C1-C18 alkyl, (C1-C18 alkyl)OH, (C1-C18 alkyl)NH2, (C1-C18 alkyl)SH, (C0-C4 alkyl)(C3-C6)cycloalkyl, (C0-C4 alkyl)(C2-C5 heterocyclic), (C0-C4 alkyl)(C6-C10 aryl)R7, and (C1-C4 alkyl)(C3-C9 heteroaryl) or R4 and R3 together with the atoms to which they are attached form a 4, 5 or 6 member heterocyclic ring;
(c) R5 is NHR6 or OH;
(d) R6 is H, C1-C8 alkyl or R6 and R2 together with the atoms to which they are attached form a 4, 5 or 6 member heterocyclic ring; and
(e) R7 is selected from the group consisting of H and OH.

### Claim 39 (depends on 10)

The compound of claim 10, further comprising an amino acid side chain on Q covalently attached to an acyl group or an alkyl group via an alkyl amine, amide, ether, ester, thioether, or thioester linkage, which acyl group or alkyl group is non-native to a naturally occurring amino acid.

### Claim 40 (depends on 39)

The compound of claim 39, wherein the amino acid to which the acyl or alkyl group is attached is at a position corresponding to position 10, 20, 24, 30, 37, 38, 39, 40, 41, 32, or 43 of a sequence comprising native glucagon, or the C-terminal amino acid.

### Claim 41

(canceled)

### Claim 42 (depends on 40)

The compound of claim 40, wherein the acyl group or the alkyl group is attached to the side chain of the amino acid through a spacer.

### Claim 43

(canceled)

### Claim 44 (depends on 10)

The compound of claim 10, wherein Q is covalently attached to one or more heterologous moieties.

### Claim 45

(canceled)

### Claim 46 (depends on 10)

The compound of claim 10 wherein Q is selected from the group consisting of SEQ ID NOs: 1-564, 566-570, 573-575, 577, 579-580, 585-612, 616, 618-632, 634-642, 647, 657-692, 694-695, 715-718, 722, 724-725, 729, 731-760, 801-878, 883-919, 1001-1275, 1301-1371, 1401-1518, and 1601-1650.

### Claim 47

(canceled)

### Claim 48 (depends on 10)

A pharmaceutical composition comprising the compound of claim 10 and a pharmaceutically acceptable carrier.

### Claim 49 (depends on 48)

A method for treating a disease or medical condition in a patient, wherein the disease or medical condition is selected from the group consisting of metabolic syndrome, diabetes, obesity, liver steatosis, and a neurodegenerative disease, comprising administering to the patient the pharmaceutical composition of claim 48 in an amount effective to treat the disease or medical condition.
